https://wtop.com/business-finance/2022/06/novavax-stock-tumbles-after-fda-brief-on-its-covid-vaccine/
Novavax stock tumbles after FDA brief
on its COVID vaccine
WTOP-TV [Washington, DC], by Jeff Clabaugh
Posted By: Ribicon, 6/4/2022 11:53:35 AM
Novavax stock lost a quarter of its value Friday after a Food and Drug Administration brief ahead of its COVID-19 vaccine’s review next week raised concerns. “Data from passive surveillance during post-authorization use in other countries indicate a higher-than-expected rate of myocarditis and pericarditis associated with the vaccine,” the briefing document noted. “However, interpretation of these passive surveillance data is not straightforward, and further evaluation is need to inform the risk associated with the vaccine, and their outcomes, as additional data emerge over time.” The document was supportive of the Novavax vaccine’s effectiveness, and it is still expected to be approved.